---
title: "The concept of innovative drugs has rebounded, with InventisBio and InnoCare Pharma reaching historical highs"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/248537066.md"
description: "In the afternoon, the innovative drug concept showed signs of recovery, with InventisBio and InnoCare Pharma both rising over 6%, reaching historical highs. Yipinhong, New Horizon, BeiGene, Borui Pharmaceutical, and Kangchen Pharmaceutical all rose by more than 5%. According to a research report from Huaxin Securities, the National Healthcare Security Administration will add a new commercial insurance innovative drug catalog in 2025, providing support for new drugs with high clinical value but payment bottlenecks. It is expected that products entering the commercial insurance catalog will receive a higher payment ratio, improving the accessibility of new drugs"
datetime: "2025-07-15T06:09:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/248537066.md)
  - [en](https://longbridge.com/en/news/248537066.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/248537066.md)
generator: "portal-rs"
---

# The concept of innovative drugs has rebounded, with InventisBio and InnoCare Pharma reaching historical highs

In the afternoon, the innovative drug concept showed signs of recovery, with InventisBio and InnoCare Pharma both rising over 6%, reaching historical highs. Yipinhong, New Horizon, BeiGene, Borui Pharmaceutical, and Kangchen Pharmaceutical all rose by more than 5%. On the news front, a research report from Huaxin Securities pointed out that in 2025, the National Healthcare Security Administration will add a new commercial insurance innovative drug catalog to support new drugs with high clinical value but payment bottlenecks. It is expected that products entering the commercial insurance catalog will receive a higher payment ratio, enhancing the accessibility of new drugs

### Related Stocks

- [688428.CN](https://longbridge.com/en/quote/688428.CN.md)
- [09969.HK](https://longbridge.com/en/quote/09969.HK.md)
- [688382.CN](https://longbridge.com/en/quote/688382.CN.md)

## Related News & Research

- [China NMPA clears InnoCare Phase III trial of mesutoclax-azacitidine in treatment-naive AML](https://longbridge.com/en/news/296164458.md)
- [US health agencies report 55 cases of E. coli and salmonella infections tied to alfalfa sprouts](https://longbridge.com/en/news/296645342.md)
- [10:16 ETVIETTEL LLEGA A REPÚBLICA DOMINICANA CON DOS DÉCADAS DE EXPERIENCIA EN TELECOMUNICACIONES INTERNACIONALES](https://longbridge.com/en/news/296683773.md)
- [CDC lifts beneficial stake in Exosens to 11.71% of capital, 13.87% of voting rights](https://longbridge.com/en/news/296499698.md)
- [08:15 ETNow's the Time: Late Summer Is the Best Season For Homebuyers to Score a Deal in These U.S. Metros](https://longbridge.com/en/news/296616885.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**